Editas Medicine (EDIT) Competitors

Editas Medicine (NASDAQ:EDIT) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Does the media prefer EDIT or PRTA?

In the previous week, Editas Medicine had 4 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Editas Medicine and 5 mentions for Prothena. Editas Medicine's average media sentiment score of 0.71 beat Prothena's score of 0.63 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts rate EDIT or PRTA?

Editas Medicine currently has a consensus target price of $6.83, suggesting a potential upside of 324.43%. Prothena has a consensus target price of $55.00, suggesting a potential upside of 469.95%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	2 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07
Prothena	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the MarketBeat Community prefer EDIT or PRTA?

Prothena received 299 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote.

Company	Underperform	Outperform
Editas Medicine	Outperform Votes 313 53.23%	Underperform Votes 275 46.77%
Prothena	Outperform Votes 612 70.43%	Underperform Votes 257 29.57%

Which has preferable valuation and earnings, EDIT or PRTA?

Prothena has higher revenue and earnings than Editas Medicine. Prothena is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$32.31M	4.17	-$153.22M	-$2.88	-0.56
Prothena	$135.16M	3.84	-$147.03M	-$2.30	-4.20

Do institutionals & insiders hold more shares of EDIT or PRTA?

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by insiders. Comparatively, 9.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, EDIT or PRTA?

Editas Medicine has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Is EDIT or PRTA more profitable?

Prothena has a net margin of -90.50% compared to Editas Medicine's net margin of -340.96%. Prothena's return on equity of -22.67% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-340.96%	-80.13%	-50.99%
Prothena	-90.50%	-22.67%	-19.68%

Summary

Prothena beats Editas Medicine on 13 of the 18 factors compared between the two stocks.